Company Epigenomics AG

Equities

ECX

DE000A37FT41

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Diagnostics & Testing

Market Closed - Xetra Other stock markets 11:36:01 2024-05-23 am EDT			5-day change	1st Jan Change
1.65 ^EUR	+0.30%		+0.61%	-12.70%

Mar. 14

Epigenomics AG Reports Earnings Results for the Full Year Ended December 31, 2023

Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.

Number of employees: 18

EUR in Million	2021	Weight	2022	Weight	Delta
In Vitro Diagnostic - Products 95.9 %	0	7.5 %	0	95.9 %	0.00%
Licensing 4.1 %	0	0.4 %	0	4.1 %	-9.09%

EUR in Million	2021	Weight	Weight	Delta
North America 54.2 %	0	4.8 %	54.2 %	-11.45%
Europe 38.6 %	0	3.0 %	38.6 %	-1.06%
Asia 7.2 %	6	92.2 %	7.2 %	-99.39%

Managers	Title	Age	Since
Frederic Hilke IRC	Investor Relations Contact	-	-
Annett Dietrich HRO	Human Resources Officer	-	-

Members of the board	Title	Age	Since
Helge Lubenow CHM	Chairman	56	16-05-24
Jochen Hummel BRD	Director/Board Member	54	Feb. 04
Alexander Link BRD	Director/Board Member	53	20-05-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	875,150	584,339 ( 66.77 %)	0	66.77 %

Name	Equities	%	Valuation
LBBW Asset Management Investmentgesellschaft mbH 0.4793 %	818	0.4793 %	1 382 €
Decalia Asset Management SIM SpA 0.3369 %	575	0.3369 %	971 €
Hauck & Aufhäuser Investment Gesellschaft SA 0.3146 %	537	0.3146 %	907 €
Universal-Investment-Gesellschaft mbH (Invt Mgmt) 0.2250 %	384	0.2250 %	649 €
Union Investment Privatfonds GmbH 0.1260 %	215	0.1260 %	363 €
Union Investment Institutional GmbH 0.0633 %	108	0.0633 %	182 €
Pioneer Investments Austria GmbH 0.0545 %	93	0.0545 %	157 €
Cominvest Asset Management GmbH 0.0516 %	88	0.0516 %	149 €
BayernInvest Kapitalverwaltungsgesellschaft mbH 0.0135 %	23	0.0135 %	39 €
Credit Suisse Asset Management Ltd. Japan 0.0123 %	21	0.0123 %	35 €

Epigenomics AG

Bertha-Benz-Strasse 5

10557, Berlin

+49 30 243 450

http://www.epigenomics.com/de/

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.65 EUR

Average target price

15.8 EUR

Spread / Average Target

+857.58%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Diagnostics & Testing

	1st Jan change	Capi.
EPIGENOMICS AG	-12.70%	1.57M
EXACT SCIENCES CORPORATION	-26.90%	9.87B
GUARDANT HEALTH, INC.	-16.78%	2.75B
BGI GENOMICS CO., LTD.	-17.50%	2.13B
VERACYTE, INC.	-24.25%	1.65B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+64.58%	1.47B
CAREDX, INC	+31.92%	811M
SEEGENE, INC.	-5.02%	733M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-29.59%	510M
CURIOX BIOSYSTEMS CO., LTD	+0.20%	300M

Bio Diagnostics & Testing